Potential SARS-CoV-2 main protease inhibitors
R Banerjee, L Perera, LMV Tillekeratne - Drug Discovery Today, 2021 - Elsevier
Highlights•The SARS-CoV-2 main protease is a prime drug target.•Coronavirus main
proteases share a structurally conserved substrate-binding region.•The structure and …
proteases share a structurally conserved substrate-binding region.•The structure and …
A revisit to the research updates of drugs, vaccines, and bioinformatics approaches in combating COVID-19 pandemic
A new strain of coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
responsible for the coronavirus disease 2019 (COVID-19) pandemic was first detected in the …
responsible for the coronavirus disease 2019 (COVID-19) pandemic was first detected in the …
Using informative features in machine learning based method for COVID-19 drug repurposing
Abstract Coronavirus disease 2019 (COVID-19) is caused by a novel virus named Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This virus induced a large …
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This virus induced a large …
In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs
Abstract Coronavirus disease (COVID-19) is an emerging pandemic that threatens the world
since the early days of 2020. Development of vaccines or new drugs against COVID-19 …
since the early days of 2020. Development of vaccines or new drugs against COVID-19 …
Drug delivery system based on PVA and clay for potential treatment of COVID-19
M Teodorescu, S Morariu - Journal of Polymer Research, 2022 - Springer
Tremendous efforts are being made around the world to develop efficient ways to
prevent/treat the novel β-coronavirus disease (COVID-19) caused by SARS-CoV-2. There …
prevent/treat the novel β-coronavirus disease (COVID-19) caused by SARS-CoV-2. There …
Antiviral activity of approved antibacterial, antifungal, antiprotozoal and anthelmintic drugs: chances for drug repurposing for antiviral drug discovery
L Abdulaziz, E Elhadi, EA Abdallah… - Journal of …, 2022 - Taylor & Francis
Drug repurposing process aims to identify new uses for the existing drugs to overcome
traditional de novo drug discovery and development challenges. At the same time, as viral …
traditional de novo drug discovery and development challenges. At the same time, as viral …
[HTML][HTML] COVID-19 and active primary tuberculosis in a low-resource setting: a case report
MA Baskara, F Makrufardi, A Dinisari - Annals of Medicine and Surgery, 2021 - Elsevier
Introduction and importance Most people infected with the COVID-19 virus will experience
mild to moderate respiratory illness. But there are few studies that explain the clinical …
mild to moderate respiratory illness. But there are few studies that explain the clinical …
[HTML][HTML] Co-infection of COVID-19 and Tuberculosis
L Kılıç, S Altın, MG Ortaköylü, ZD Kanmaz… - Turkish Thoracic …, 2022 - ncbi.nlm.nih.gov
Co-infection of COVID-19 and Tuberculosis - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Preview …
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Preview …
An Updated and Focused Review on Heterocyclic Inhibitors for SARSCoV and SARS-CoV-2 3CLpro
Background: SARS-CoV and SARS-CoV-2 are exceedingly contagious and typically result
in major respiratory illnesses (acute respiratory syndrome). The public health is facing …
in major respiratory illnesses (acute respiratory syndrome). The public health is facing …
Is 3% Eu3+ doping in ZnO unique? An investigative case study of photocatalytic descriptors using multiparameter approach
A Tahir, T Jan, I Irshad, A Ganie, Z ul Islam… - Physica Scripta, 2024 - iopscience.iop.org
The study focused on synthesizing Europium (Eu 3+) doped ZnO hybrid materials using a
hydrothermal method, aiming to create Eu 3+: ZnO nanocomposites, which were …
hydrothermal method, aiming to create Eu 3+: ZnO nanocomposites, which were …